Dr. Amy Rudolph is a leader in the pharmaceutical industry with over 25 years of experience in both US and global large pharma. She has an accomplished track record with multiple product launches across a broad portfolio of diseases and brings deep experience in discovery, clinical development, medical affairs, and market access.

She is currently with Boehringer Ingelheim, serving as Head of Global Medical Affairs and Cross-TA Medical Affairs. In this role, Dr. Rudolph led a transformation to build a market-leading Medical Affairs organization across regions and countries, with a focus on medical leadership in external engagement, digital/AI, integrated evidence, advanced analytics, and learning.

Prior to joining Boehringer Ingelheim, Dr. Rudolph held diverse leadership roles at Novartis Pharmaceutical Corporation, where she served as Head of HCS (Healthcare Systems) Partnerships in Global Drug Development and, within Global Medical Affairs, as Head of Evidence and Launch Excellence. At Pfizer Inc., Dr. Rudolph oversaw the atherosclerosis and stroke platforms, early development, and licensing/technology evaluations. She also held progressive research scientist roles at G.D. Searle/Pharmacia/Pfizer.

Dr. Rudolph holds a PhD in Biochemistry and Molecular Biology from Washington University in St. Louis, MO, and has published 13 patents along with numerous articles spanning preclinical research, drug development, and real-world evidence.